Arbutus Biopharma Logo
Treatment with Arbutus’ Imdusiran and VTP-300 Achieves Statistical Significance in Lowering HBsAg Levels
June 06, 2024 11:15 ET | Arbutus Biopharma Corporation
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation...
Arbutus Biopharma Logo
Arbutus’ Imdusiran with Short Course Interferon Achieves Sustained Undetectable HBsAg, a Necessity for HBV Functional Cure
June 05, 2024 02:30 ET | Arbutus Biopharma Corporation
At the end of treatment, 33.3% of patients receiving imdusiran for 48 weeks, interferon (IFN) for 24 weeks and ongoing nucleoside analogue (NA) therapy achieved undetectable levels of HBsAg that were...
avacta.png
Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 05, 2023 02:00 ET | Avacta Group
5 October 2023 Avacta Group plc (“Avacta” or the “Group” or the “Company”) Avacta to present promising new data from Affimer® and pre|CISIONTM platform assets at AACR-NCI-EORTC International...
Logo.png
Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference
May 04, 2023 16:05 ET | Cocrystal Pharma, Inc.
BOTHELL, Wash., May 04, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (Cocrystal or the Company) announces that new data from its CC-42344 Phase 1 influenza A Study was presented...
qualia_logo.jpg
Survey: Home Buying Surge Highlights Need for Home Closing Consumer Resources
September 09, 2021 10:03 ET | Qualia
SAN FRANCISCO, Calif., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Qualia, the leading digital real estate closing platform, today announced the release of its Homebuyer Sentiment Index, which shined a...